Lynparza successful in pancreatic cancer trial
AstraZeneca and MSD’s Lynparza is the first PARP inhibitor to demonstrate a benefit in pancreatic cancer, having hit targets in the Phase III POLO trial.
Read More
Tag: oncology collaboration
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
